Page 3 - Brian Plummer News Today

New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor

Analysis of Real-World Data in People Living With HIV in the International BICSTaR Study to be Presented at EACS 2021 Also Confirm the Long-Term Efficacy and Safety Profile of Biktarvy – Gilead Sciences, Inc. today announced the company’s upcoming contributions to the 18th European AIDS Conference taking place virtually and onsite in London from October 27-30. Forty-four studies from Gilead’s HIV research and ...

- Analysis of Real-World Data in People Living With HIV in the International BICSTaR Study to be Presented at EACS 2021 Also Confirm the Long-Term Efficacy and Safety Profile of Biktarvy - Gilead

U.S. Food and Drug Administration Approves Expanded Indication of Gilead’s Biktarvy® for Treatment of HIV-1 in Pediatric Populations

EMA MAA Validation Follows Submission of NDA for Lenacapavir to the U.S. FDA – – If Authorized, Lenacapavir Would be the First Capsid Inhibitor and the Only HIV-1 Treatment Option Administered Twice Yearly – Gilead Sciences, Inc. today announced that the company’s Marketing Authorization Application for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, has been fully validated and is now ...

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options If Approved, Lenacapavir Would be the First Capsid Inhibitor and the Only HIV-1 Treatment Option Administered Every 6 Months – Gilead Sciences, Inc. announced today that the company completed submission of a New Drug Application to the U.S. Food and Drug Administration seeking approval of le...

March 09, 2021 – – Late-Breaking Preclinical Data Support Further Study of Lenacapavir as a Long-Acting Agent for HIV Prevention – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today presented additional results from the Phase 2/3 CAPELLA trial evaluating the company’s investigational, long-acting HIV-1 capsid inhibitor, lenacapavir, in heavily treatment-experienced people with multi-drug resistant HIV-1 infection. The data build on the positive primar...

Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROI 98% of Treatment-Naïve Patients Achieved and Maintained Undetectable Viral Load with Biktarvy Through Four Years in the Open-Label Extension Phase of Two Phase 3 Studies – – Treatment-Naïve Adults Reached and Maintained Undetectable Viral Load with Biktarvy for Certain Transmitted-Drug Resistance and with No Treatment-Emergent Resistance Through 144 Weeks – ...

While COVID-19 has certainly altered recruiting across the country, it hasn’t stopped coaches from discovering elite talent.

Published December 23. 2020 12:10AM  By TOM HAYS, Associated Press NEW YORK — A Delta flight out of New York City was halted after a Florida couple traveling with a Great Dane puppy fled the aircraft with the pet using an emergency slide, an airline spokesperson and authorities said Tuesday. The incident involving Antonio Murdock and Brianna Greco occurred on Monday as the jet was on a runway leaving for a flight from LaGuardia Airport to Atlanta, said the spokesperson, Morgan Durrant. Witne...